Anti-TGFBI antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project
(www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these
protocols and other useful information about Prestige Antibodies and the HPA, visit .
TGFBI (transforming growth factor β induced) is a secretory protein, the secretion of which is induced by TGFβ in fibroblasts. It was first recognized in TGFβ-treated human lung adenocarcinoma cell line (A549). It is a highly conserved 68kDa protein, composed of 683 amino acids. It is predominantly expressed by fibroblasts, muscle cells and keratinocytes.
TGFBI (transforming growth factor β induced) in involved in the initiation of morphongensis, inflammation, cell division, adhesion, proliferation, migration and differentiation. It acts as linker protein mediating the interaction of integrin to ECM (extracellular matrix) proteins. It is up-regulated in multiple human cancers, such as colorectal cancer, where its expression is linked to poor prognosis. It acts as a regulator of cyclins and CDKs (cyclin dependent kinases) in melanomas, and is highly secreted by metastatic melanoma cell. Thus, it facilitates growth and survival in metastatic melanoma cells. In HBV (hepatitis B virus)-related HCC (hepatocellular carcinoma), the aberrant expression of this protein is linked to the oncogenic potential of HBV S gene.
